FDA Approved Indications for this Orphan Drug:Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years to 4 years of age.
FDA Marketing Approval issued as of:
Orphan Drug exclusivity ends on:
Company Making and Marketing this drug:
FDA Designation Date:
FDA Drug Designation:
Treatment of juvenile rheumatoid arthritis